These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31495683)

  • 1. Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic Rabbits.
    Parolini C; Adorni MP; Busnelli M; Manzini S; Cipollari E; Favari E; Lorenzon P; Ganzetti GS; Fingerle J; Bernini F; Chiesa G
    Can J Cardiol; 2019 Oct; 35(10):1400-1408. PubMed ID: 31495683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type).
    Ibanez B; Giannarelli C; Cimmino G; Santos-Gallego CG; Alique M; Pinero A; Vilahur G; Fuster V; Badimon L; Badimon JJ
    Atherosclerosis; 2012 Jan; 220(1):72-7. PubMed ID: 22030095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging.
    Parolini C; Marchesi M; Lorenzon P; Castano M; Balconi E; Miragoli L; Chaabane L; Morisetti A; Lorusso V; Martin BJ; Bisgaier CL; Krause B; Newton RS; Sirtori CR; Chiesa G
    J Am Coll Cardiol; 2008 Mar; 51(11):1098-103. PubMed ID: 18342229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport.
    Yuan W; Yu B; Yu M; Kuai R; Morin EE; Wang H; Hu D; Zhang J; Moon JJ; Chen YE; Guo Y; Schwendeman A
    J Control Release; 2021 Jan; 329():361-371. PubMed ID: 33188828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.
    Guo Y; Yuan W; Yu B; Kuai R; Hu W; Morin EE; Garcia-Barrio MT; Zhang J; Moon JJ; Schwendeman A; Eugene Chen Y
    EBioMedicine; 2018 Feb; 28():225-233. PubMed ID: 29361501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Compendium of the Biological Effects of Apolipoprotein A-I
    Parolini C
    J Pharmacol Exp Ther; 2020 Jan; 372(1):54-62. PubMed ID: 31649050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?
    Tardif JC
    J Clin Lipidol; 2010; 4(5):399-404. PubMed ID: 21122683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.
    Fawaz MV; Kim SY; Li D; Ming R; Xia Z; Olsen K; Pogozheva ID; Tesmer JJG; Schwendeman A
    J Pharmacol Exp Ther; 2020 Feb; 372(2):193-204. PubMed ID: 31776208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.
    Diditchenko S; Gille A; Pragst I; Stadler D; Waelchli M; Hamilton R; Leis A; Wright SD
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2202-11. PubMed ID: 23868939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides.
    Gomaraschi M; Calabresi L; Rossoni G; Iametti S; Franceschini G; Stonik JA; Remaley AT
    J Pharmacol Exp Ther; 2008 Feb; 324(2):776-83. PubMed ID: 18042829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization.
    Tang J; Li D; Drake L; Yuan W; Deschaine S; Morin EE; Ackermann R; Olsen K; Smith DE; Schwendeman A
    J Lipid Res; 2017 Jan; 58(1):124-136. PubMed ID: 27881716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury.
    Calabresi L; Gomaraschi M; Rossoni G; Franceschini G
    Pharmacol Ther; 2006 Sep; 111(3):836-54. PubMed ID: 16960983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.
    Gille A; Easton R; D'Andrea D; Wright SD; Shear CL
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2106-14. PubMed ID: 24969776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic evaluation of the effect of different apolipoprotein A-I mimetic peptides on the performance of synthetic high-density lipoproteins in vitro and in vivo.
    Yuan W; Ernst K; Kuai R; Morin EE; Yu M; Sviridov DO; Tang J; Mei L; Li D; Ackermann R; Remaley AT; Schwendeman A
    Nanomedicine; 2023 Feb; 48():102646. PubMed ID: 36549559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-density lipoprotein infusion therapy: A review.
    Brewer HB; Schaefer EJ; Foldyna B; Ghoshhajra BB
    J Clin Lipidol; 2024; 18(3):e374-e383. PubMed ID: 38782655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human apolipoprotein A-I exerts a prophylactic effect on high-fat diet-induced atherosclerosis via inflammation inhibition in a rabbit model.
    Li J; Wang W; Han L; Feng M; Lu H; Yang L; Hu X; Shi S; Jiang S; Wang Q; Ye L
    Acta Biochim Biophys Sin (Shanghai); 2017 Feb; 49(2):149-158. PubMed ID: 28069582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.
    Ibanez B; Vilahur G; Cimmino G; Speidl WS; Pinero A; Choi BG; Zafar MU; Santos-Gallego CG; Krause B; Badimon L; Fuster V; Badimon JJ
    J Am Coll Cardiol; 2008 Mar; 51(11):1104-9. PubMed ID: 18342230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics.
    Li D; Fawaz MV; Morin EE; Ming R; Sviridov D; Tang J; Ackermann R; Olsen K; Remaley AT; Schwendeman A
    Mol Pharm; 2018 Jan; 15(1):83-96. PubMed ID: 29141139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic High-Density Lipoprotein (sHDL) Inhibits Steroid Production in HAC15 Adrenal Cells.
    Taylor MJ; Sanjanwala AR; Morin EE; Rowland-Fisher E; Anderson K; Schwendeman A; Rainey WE
    Endocrinology; 2016 Aug; 157(8):3122-9. PubMed ID: 27253994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo.
    Puranik R; Bao S; Nobecourt E; Nicholls SJ; Dusting GJ; Barter PJ; Celermajer DS; Rye KA
    Atherosclerosis; 2008 Jan; 196(1):240-247. PubMed ID: 17586510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.